Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.53 |
| ▸ | RXRG | P48443 | 10/20 | 0.53 |
| ▸ | RXRB | P28702 | 9/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628814 | 0.92 | RXRA (0.49) | RXRARXRGRXRBAKR1B1AGBL2 | |
| SCHEMBL10029567 | 0.82 | AGBL2 (0.38) | RXRARXRGRXRBAKR1B1PTGDR2 | |
| SCHEMBL630423 | 0.79 | RXRA (0.58) | RXRARXRGRXRB | |
| Propionic Acid SCHEMBL10435305 | 0.78 | RXRA (0.43) | RXRARXRGRXRB | |
| SCHEMBL628828 | 0.77 | F2RL3 (0.38) | RXRARXRGRXRBTRPA1 | |
| SCHEMBL629167 | 0.77 | RXRA (0.53) | RXRARXRGRXRB | |
| SCHEMBL628637 | 0.74 | RXRA (0.53) | RXRARXRGRXRBTRPA1PTGDR2 | |
| SCHEMBL631128 | 0.74 | RXRA (0.50) | RXRARXRGRXRB | |
| SCHEMBL630413 | 0.74 | RXRA (0.50) | RXRARXRGRXRB | |
| SCHEMBL630601 | 0.74 | RXRA (0.50) | RXRARXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| EP-2419412-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120741-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | RBP4, RBP1, FABP4 | RXRA 11/4885RXRG 10/4885RXRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.